Drug discovery and preclinical testing of drug candidates for developmental and epileptic encephalopathies.

ABSTRACT: Drug development for developmental and epileptic encephalopathies (DEEs) follows different strategies on one hand including disease-targeting precision medicine approaches considering the genetic variants and pathomechanisms in DEEs and on the other hand including therapeutic approaches with novel targets or second-generation drug candidates that may be of interest beyond selected DEEs. Although the first group of approaches can only be tested in dedicated DEE models, assessment in induced non-specific seizure and epilepsy models may provide valuable information if the mechanism of action implies a broader spectrum of efficacy. Data from such models can inform about general anti-seizure efficacy, efficacy against different seizure types including a possible broad-spectrum potential, dose r

SUBMITTER: Potschka H 

PROVIDER: S-EPMC12779334 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature